Despite facing a patent cliff of up to $300 billion by 2030 and knowing that most innovation is externally sourced, big pharma's M&A activity remains surprisingly tepid. This paradox suggests a major disconnect between strategic necessity and the industry's current risk appetite or deal-making capacity.

To successfully acquire a shelved asset from a large pharma company, you must find a high-level internal advocate—what Annette Bakker calls a "Frida." This person must believe in the project and possess the influence to navigate internal bureaucracy and champion the out-licensing effort, which is often complex and not a corporate priority.

The industry's costly drug development failures are often attributed to clinical issues. However, the root cause is frequently organizational: siloed teams, misaligned incentives, and hierarchical leadership that stifle the knowledge sharing necessary for success.

K-36's lead drug was acquired from Novartis not because it was a failed asset, but because it became available during a strategic reorganization. This illustrates a key opportunity for biotech startups: licensing promising preclinical assets that no longer fit a large pharmaceutical company's immediate development focus.

Shelved drugs aren't a monolith. They typically fall into four categories: 1) dropped due to a strategic shift, 2) orphaned after a biotech acquisition, 3) returned to a small company after a partnership ends, or 4) legally inaccessible after a company's bankruptcy. Understanding these archetypes is key to tailoring a rescue strategy.

A practical way to find potentially abandoned drug assets is to scan the public ClinicalTrials.gov database. Andrew Lo suggests identifying trials that are still listed as active but have not been updated for a significant period. This public data provides a scalable, low-cost starting point for discovering valuable candidates that pharma companies are no longer pursuing.

Discontinued drugs aren't hard to identify; the real challenge is navigating the out-licensing process inside a large pharma company. Without an internal champion to drive the complex approvals for a non-priority asset, promising drugs can languish on the shelf due to corporate inertia, not a desire to hide them.

As large pharmaceutical companies shift focus to acquiring clinically validated assets, a gap has emerged in early-stage development. Smaller and mid-sized pharmas, unable to compete on price for late-stage assets, are now incentivized to take on more risk and partner earlier, driving innovation.

The ultimate vision is a dynamic marketplace where pharma companies routinely list their shelved assets. This "eBay for drug candidates" would allow interested parties—from biotechs to patient advocacy groups—to access information, assess opportunities, and bid on developing these assets, creating a systematic and efficient repurposing pipeline.